These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Lennard MS; Iyun AO; Jackson PR; Tucker GT; Woods HF Pharmacogenetics; 1992 Apr; 2(2):89-92. PubMed ID: 1302046 [TBL] [Abstract][Full Text] [Related]
6. Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of southern Africa. Sommers DK; Moncrieff J; Avenant J Hum Toxicol; 1989 Jan; 8(1):39-43. PubMed ID: 2714809 [TBL] [Abstract][Full Text] [Related]
7. Dextromethorphan metabolism in Jordanians: dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation. Irshaid YM; al-Hadidi HF; Latif A; Awwadi F; al-Zoubi M; Rawashdeh NM Eur J Drug Metab Pharmacokinet; 1996; 21(4):301-7. PubMed ID: 9074894 [TBL] [Abstract][Full Text] [Related]
8. Debrisoquine and metoprolol oxidation in Zambians: a population study. Simooya OO; Njunju E; Hodjegan AR; Lennard MS; Tucker GT Pharmacogenetics; 1993 Aug; 3(4):205-8. PubMed ID: 8220440 [TBL] [Abstract][Full Text] [Related]
9. Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Sommers DK; Moncrieff J; Avenant J Hum Toxicol; 1989 Sep; 8(5):365-8. PubMed ID: 2807305 [TBL] [Abstract][Full Text] [Related]
10. Age might influence the frequency distribution of metoprolol hydroxylation polymorphism in a Chinese population. Wan J; Xie YH; Xia H; Lu YQ Pharmacol Toxicol; 1997 Apr; 80(4):167-70. PubMed ID: 9140135 [TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989 [TBL] [Abstract][Full Text] [Related]
12. Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype. Lennard MS; Tucker GT; Woods HF; Silas JH; Iyun AO Br J Clin Pharmacol; 1989 May; 27(5):613-6. PubMed ID: 2757883 [TBL] [Abstract][Full Text] [Related]
13. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population. Horai Y; Taga J; Ishizaki T; Ishikawa K Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455 [TBL] [Abstract][Full Text] [Related]
14. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974 [TBL] [Abstract][Full Text] [Related]
15. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Lennard MS; Tucker GT; Silas JH; Woods HF Xenobiotica; 1986 May; 16(5):435-47. PubMed ID: 2874665 [TBL] [Abstract][Full Text] [Related]
17. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; Ingelman-Sundberg M Eur J Clin Pharmacol; 1996; 51(2):117-22. PubMed ID: 8911874 [TBL] [Abstract][Full Text] [Related]
18. Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population. Vincent-Viry M; Muller J; Fournier B; Galteau MM; Siest G Clin Chem; 1991 Mar; 37(3):327-32. PubMed ID: 2004438 [TBL] [Abstract][Full Text] [Related]
19. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study. Bozkurt A; Basçi NE; Işimer A; Sayal A; Kayaalp SO Eur J Drug Metab Pharmacokinet; 1996; 21(4):309-14. PubMed ID: 9074895 [TBL] [Abstract][Full Text] [Related]